Review Article

Hydroxychloroquine retinal toxicity- Can we do better with SD-OCT?

Logandran Vijaya Kumar1,*1, Kursiah Mohd Razali2, Wan Hazabbah Wan Hitam3

1 Ministry of Health, Malaysia
2 Hospital Raja Permaisuri Bainun, Perak, Malaysia
3 Universiti Sains, Malaysia

ABSTRACT

Introduction: Hydroxychloroquine used in the management of connective tissue diseases also used to treat a wide spectrum of diseases. This disease-modifying anti-rheumatic drug can cause irreversible retinal damage and there are preferred practice guidelines for early screening to aid ophthalmologists and all those involved in the management of these patients. Spectral-Domain Optical Coherence Tomography (SD-OCT) currently an important tool in early detection of possible toxicity. Even with the current guideline-recommended 5mg/kg/day dosage, a baseline SD-OCT of the macula should be taken and repeated at 5 years. Many cross-sectional studies using SD-OCT have shown earlier retina damages, but none had monitored continuously from the beginning of Hydroxychloroquine usage.

Purpose: To evaluate sequential changes of the retina thickness in patients newly treated with hydroxychloroquine.

Materials and Methods: We compared the mean central macular and Retinal Nerve Fiber Layer (RNFL) thickness pre, 3 months and 6 months post hydroxychloroquine using SD-OCT in order to find an association between them over the three time-points. 33 previously healthy patients who were newly confirmed clinically and serologically with connective tissue disease planned for hydroxychloroquine who fulfilled the inclusion and exclusion criteria were recruited over 2 years. In consideration of selection criteria and drop-out rate, finally, 26 patients were included in the study.

Results: 26 eyes of 26 patients (20 females and 6 males) were included in the study. The mean age was 33.92. The macula was significantly thinner (P<0.05) at superior (P<0.032), temporal (P<0.025), and inferior (P<0.016) parafoveal areas. RNFL showed significantly thinning at the temporal quadrant (P<0.041). Further analysis showed significant occurrences of parafoveal inferior thinning at 3 (P<0.035) and 6 (P<0.032) months. Correlation analysis between parafoveal thinning and the mean optic disc RNFL showed a significant result (p =0.004, r=0.55). The mean optic disc RNFL thickness significantly affected lesser (p =0.004, r²=0.302) than the perifoveal area (p =0.001, r²=0.784) when compared to the typical parafoveal pattern of thinning in this toxicity.

Conclusion: There is a need for an earlier repetition of SD-OCT imaging before 5 years to detect potential toxicity. Involvement of RNFL requires further investigation and monitoring.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Hydroxychloroquine is an immunomodulator drug often used as a disease-modifying antirheumatic drug (DMARDs) and acts by inhibition and modulation of immune responses.
Hydroxychloroquine also used in many conditions including diabetes mellitus, heart disease, graft-versus-host disease, adjunctive cancer therapy, systemic vasculitis and Coronavirus Disease 2019 (COVID-19).\textsuperscript{1–4}

Hydroxychloroquine retinal toxicity is a serious condition with potential retinal damage and has a higher prevalence than previously documented.\textsuperscript{5} The mechanism involved binding of hydroxychloroquine to the melanin of retinal pigmented epithelium, inhibits its activity over a prolonged period,\textsuperscript{6} causing thinning to both the inner and outer retina.\textsuperscript{7} Other mechanism is retinal vasculitis with retinal microinfarcts initiating the RNFL and macular thinning (inner retina), and arteriolar narrowing and disc pallor in higher concentration.\textsuperscript{8} Rare mechanism with early toxicity occurred with genetic predisposition to hydroxychloroquine\textsuperscript{9} and polymorphisms in the cytochrome P450 gene that increased hydroxychloroquine blood concentration.\textsuperscript{10}

Visual acuity is usually good until the development of severe toxicity, so any efficient screening should detect structural changes (retina damage) before functional deterioration. Spectral Domain Optical Coherence Tomography (SD-OCT) is an important addition for early detection of hydroxychloroquine toxicity. The SD-OCT cross-section images at mild toxicity are subtle or unremarkable. Moderate toxicity has a distinctive discontinuity of the photoreceptor inner segment/outer segment.\textsuperscript{11} With time, the outer nuclear layer thinning occurred.\textsuperscript{12} However, the outer retinal thickness remains normal despite the destruction of outer segment photoreceptors creating the “flying saucer” or sombrero sign.\textsuperscript{13} Severe toxicity includes disruption of the outer retina and RPE.

The recommended dose of hydroxychloroquine, ophthalmology baseline, and follow-ups plus the screening tools changes over the years was summarized in (Table 1). The paradigm shift of these guidelines tally with discoveries of increased prevalence and the reversible retinal changes with early detection and intervention using SD-OCT. The current recommended dose is 5mg/kg real body weight per day with a baseline SD-OCT and re-imaging at 5 years of hydroxychloroquine usage to most patients classified as a low-risk group.\textsuperscript{5}

Many cross-sectional studies using SD-OCT have shown earlier retina damages, but none had measured continuously from the beginning of hydroxychloroquine usage. Thus, the purpose of this pilot prospective cohort study is to evaluate the sequential changes of retina thickness in patients newly treated with hydroxychloroquine using the latest guideline recommendations.

2. Materials and Methods

This study was conducted after obtaining approvals from the Ethical Committee of Universiti Sains Malaysia and the Ministry of Health of Malaysia per the Declaration of Helsinki for Human Research (USM/IEPem/ I6010029 and NMRR-16-116-28987 (IIR)). The sample size was calculated using closest studies using G*Power version 3.1.9.2 for Windows available at http://www.gpower.hhu.de We have summarized the methodology in (Figure 1). Written consent was obtained from all patients.

These patients underwent complete ocular and systemic history with the full ocular examination via slit lamp biomicroscope (Topcon Corp, Japan) and Volk Super 66 stereo fundus lens and then OCT macula and Optic disc (Cirrus-HD OCT 4000 software version 5.0, Carl Zeiss Meditec, Inc, Dublin, CA) pre, and 6 months of hydroxychloroquine treatment. At 3 months of hydroxychloroquine treatment, only OCT measurements were obtained in patients except for any visual symptoms where a complete ocular examination was conducted. Only tests that yielded signal strength of at least 6 and above were taken for interpretation to ensure the accuracy of the result.

A total of 33 patients were recruited. Two patients did not fulfill the selection criteria and five patients were lost to follow up. 26 patients were studied as per the protocol and included for analysis. Data collection and analysis were performed using the Statistical Package for the Social Sciences (SPSS) version 24 (SPSS, Chicago, IL, USA). Descriptive statistics were used to summarize the basic characteristics of the patients. Normally distributed data were expressed as mean ± standard deviation. All values were tested for normal distribution in all groups. Repeated Measured ANOVA test used to compare the macular thickness and RNFL thickness pre, 3 months, and 6 months. A P value of less than 0.05 (P<0.05) was considered significant.

3. Results

3.1. Demographic data

We summarize demographic characteristics of the patients in (Table 2). Our patients were young with a mean age of 33.92 years. Females were predominant (76.9%). Malay race was the most (50%). SLE is the most common disease (57.7%). Generally, all the patients having good visual acuity and vision remain unchanged for the period of this study except the 3 patients with 6/12 visual acuity who improved with glasses prescription and/or artificial tears.
Fig. 1: Methodology of the study
| Recommended dosage | RCOphth, 1993 | RCOphth, 1998 | AAO, 2002 | RCOphth, 2004 | RCOphth, 2009 | AAO, 2011 | AAO, 2017 | RCOphth, 2018 |
|-------------------|-------------|-------------|---------|-------------|-------------|---------|---------|-------------|
| Recommended dosage | 6.5 mg/kg lean weight | 6.5 mg/kg lean weight | 6.5 mg/kg lean weight | 6.5 mg/kg lean weight | 6.5 mg/kg lean weight | 5.0 mg/kg real weight | 5.0 mg/kg real weight |

| Baseline screening | Respective disciplines monitoring with renal and liver function, history of visual symptoms, near VA | Respective disciplines monitoring with Amsler Chart (preferably red on black) and/or HVF 10-2 | Respective disciplines monitoring when starting High and Low risk as AAO 2002 |
|-------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Ophthalmology further screening | Nil | Nil | Advised for an ophthalmologist assessment |

Assessment should be done by an ophthalmologist within 1 year of starting therapy. Major toxicity factors:
- Daily Dose (more than 5 mg/kg)
- Duration of use (more than 5 years).
- Renal disease (subnormal glomerular filtration rate)
- Concomitant drugs (Tamoxifen).
- Retina and Macular diseases.

Lesser toxicity factors:
- Age (Elderly)
- Liver Disease
- Genetic Factors

After 5 years if low risk (earlier based on age) or annual if presence of major risk

Assessment should be done by an ophthalmologist within six months, but not more than 12 months, of starting therapy with a colour retinal photograph and SD-OCT scans of the macula. Major and Lesser toxicity factors as AAO 2017

Continued on next page
| Important tools for screening | VA and Amsler Test | VA and Amsler Test | VA, Amsler Chart and/or HVF 10-2 | VA and Amsler Chart | Fundus photography, Amsler Chart (red on black) | Suggested OCT, FAF imaging and visual electrophysiological tests | SD-OCT and HVF (10-2 for Caucasian and 24-2 or 30-2 for Asian) | SD-OCT, widefield FAF and HVF 10-2 HVF 30-2 if abnormal FAF HVF defect with normal SD-OCT and FAF require multi focal ERG |
|-----------------------------|-------------------|-------------------|-------------------------------|-------------------|-----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Not recommended for screening | Nil               | Nil               | Nil                           | Nil               | Nil                                           | Fundus Photography, Time Domain OCT, Fluorescein angiography, Full field ERG, Amsler grid, Colour testing and EOG | Fundus Photography, Time Domain OCT, Fluorescein angiography, Full field ERG, Amsler grid, Colour testing and EOG | SD-OCT, widefield FAF and HVF 10-2 HVF 30-2 if abnormal FAF HVF defect with normal SD-OCT and FAF require multi focal ERG |
| Long term follow-up         | No further ophthalmic examination is necessary unless the patient becomes symptomatic | Individual arrangements after 5 years | None for low risk, Annual for high risk | May not be required in patients taking low (6.5 mg/kg) doses of hydroxychloroquine | Most patient does not require follow-ups after check at 5 years | Annual screening in all patient after 5 years | Annual screening in all patient after 5 years | Annual screening in all patient after 5 years |

RCOphth: Royal College of Ophthalmologists; AAO: American Academy of Ophthalmology; HVF: Humphrey visual field; ERG: Electro-retinogram; EOG: Electro-oculogram; VA: Visual Acuity; SD-OCT: Spectral Domain Optical Coherence Tomography; FAF: Fundus Autofluorescence; Italic words: Updated in the latest guidelines; Bold & Italic words: Removed from the latest guideline
Table 2: Demographic characteristics of patients, (n=26)

| Parameters       | Mean (SD) | Frequency (%) |
|------------------|-----------|---------------|
| Age              | 33.92 (8.75) |               |
| Gender           |           |               |
| Male             | 6 (23.1%)  |               |
| Female           | 20 (76.9%) |               |
| Race             |           |               |
| Malay            | 13 (50.0%) |               |
| Chinese          | 5 (19.2%)  |               |
| Indian           | 8 (30.8%)  |               |
| Diagnosis        |           |               |
| SLE              | 15 (57.7%) |               |
| RA               | 7 (26.9%)  |               |
| Others           | 4 (15.4%)  |               |
| Initial Visual Acuity* |       |               |
| 6/6              | 9 (34.6%)  |               |
| 6/9              | 14 (53.8%) |               |
| 6/12             | 3 (11.5%)  |               |

Comparing the central macular thickness and optic disc retinal nerve fiber layer (RNFL) using Cirrus SD-OCT in patients with connective tissue diseases on hydroxychloroquine pre-treatment, 3 months, and 6 months post-treatment.

Comparison of mean central macular thickness and optic disc RNFL thickness were summarized in (Table 3). Generally, the macula and RNFL were thinner post-treatment. Significant thinning occurred at superior, temporal, and inferior parafoveal areas and at temporal quadrant RNFL.

Comparison of the mean central macular and optic disc retinal nerve fiber layer (RNFL) thickness using Repeated Measured ANOVA test, n=26.

Post-hoc Bonferroni correction was done to establish changes of the significant retina thinning from (Table 3) over 3 months and 6 months and is summarized in (Table 4). The inferior parafoveal area showed significant retinal thinning at 3 months and 6 months when compared with the pre-treatment group.

Linear Regression analysis to predict future thinning in the mean optic disc RNFL and the perifoveal areas based on parafoveal thinning from (Table 4) is summarized in (Table 5). All areas showed significant findings with the mean optic disc RNFL thickness significantly affected lesser (p =0.004, r²=0.302) than the parafoveal area (p =0.001, r²=0.784) when compared to the parafoveal thinning. Correlation analysis (Not Shown in the table) between parafoveal thinning and the mean optic disc RNFL also showed a significant result (p =0.004, r=0.55).

4. Discussion and Conclusion

This study showed that there were significant thinning in mean macular thickness at parafoveal superior, temporal, and inferior areas. (Table 3). These changes could be the precursor to a future localized area of photoreceptor loss noted in moderate toxicity by SD-OCT. Our timelines are much earlier than Eric Chen et al.13 who showed that the parafoveal thinning can be identified by SD-OCT in patients receiving hydroxychloroquine by 2 years. Likewise, SD-OCT cross-section quantitative analysis of the macula by Pasadhika et al.22 found significant thinning of mean inner retinal thickness with the usage of hydroxychloroquine as early as 6 years even before ophthalmoscopic fundus changes. However, a recent study of hydroxychloroquine among SLE patients had shown that there are insignificant retinal changes with SD-OCT over 5 years duration.23 But, over 99% of their patients take less than 5 mg/kg/day of HCQ and more than 92% prescribed a dose 250 mg/day which differs enormously in daily practice. Thus, repeated measurements of macular thickness to detect early thinning is relevant while quantitative analysis (such as HD Raster with 6mm Vertical x 9mm Horizontal scan area) would only be fruitful at a later stage.

The parafoveal inferior area showed significant retinal thinning at 3 months and 6 months after hydroxychloroquine usage (Table 4) which corresponded to the typical pattern of this toxicity and coincided with a recent large study of patients using hydroxychloroquine for less than 5 years duration.24 However, two studies had documented that the typical parafoveal distribution of toxicity is not common in Asians, who show a pericentral pattern of foveal thinning.25,26 But this parafoveal pattern in the first study was observed in Korean patients while the second study although include East Asian, Southeast Asian, and Filipinos, the total percentage of Asian was only 18%. They also found that 76% of patients had typical parafoveal changes, while only 12% each showed a parafoveal or mixed pattern. In our study, focusing on Asian patients, we found parafoveal involvement to be the first sign of toxicity. Similarly, the latest review in Korean patients showed predominantly parafoveal and mixed patterns.27 Another study showed that Hydroxychloroquine initially involves the parafovea, but becomes diffuse across the macula as damage progresses.28 With parafoveal thinning being a typical pattern, repeat of SD-OCT prior to 5 years should be done and compared to baseline values and once there is thinning should prompt for HVF 10-2 in Asians (instead of HVF 24-2) as it has better resolution and still able to detect the parafoveal defect.

The typical parafoveal thinning could predict future thinning in other areas as shown in our study (Table 5). Among all, perifoveal area showed the highest impact as compared to fovea because fovea is protected by foveal avascular zone. Thus, repeat of SD-OCT prior to 5 years should look for new areas of thinning instead of looking for worsening of the value of the same area. Parafoveal area thinning could also influence the mean disc RNFL thickness and this new finding could be important in future
### Table 3: Comparison of the mean central macular and optic disc retinal nerve fiber layer (RNFL) thickness using Repeated Measured ANOVA test, n=26

|                     | Pre-treatment mean(SD) | 3 months post treatment mean(SD) | 6 months post treatment mean(SD) | F statistics | P value |
|---------------------|------------------------|---------------------------------|---------------------------------|--------------|---------|
| **Macula Thickness**|                        |                                 |                                 |              |         |
| Foveal              | 242.00 (23.45)         | 239.69 (23.57)                  | 239.08 (24.64)                  | 1.94         | 0.166   |
| Superior Parafoveal | 317.81 (14.40)         | 315.46 (13.76)                  | 309.62 (21.49)                  | 1.94         | 0.032*  |
| Temporal Parafoveal| 302.27 (12.87)         | 299.58 (14.63)                  | 299.38 (14.94)                  | 1.94         | 0.025*  |
| Inferior Parafoveal| 311.73 (15.89)         | 309.73 (15.95)                  | 306.85 (20.15)                  | 1.94         | 0.016*  |
| Nasal Parafoveal    | 319.89 (15.62)         | 317.85 (16.88)                  | 316.88 (19.58)                  | 1.94         | 0.076   |
| Superior Perifoveal  | 285.31 (18.11)         | 282.23 (16.69)                  | 282.38 (19.79)                  | 1.82         | 0.184   |
| Temporal Perifoveal  | 256.85 (11.55)         | 255.35 (11.08)                  | 255.19 (13.08)                  | 1.41         | 0.253   |
| Inferior Perifoveal  | 267.08 (15.15)         | 264.58 (14.60)                  | 266.96 (16.77)                  | 1.25         | 0.294   |
| Nasal Perifoveal     | 300.23 (17.68)         | 298.35 (18.27)                  | 297.19 (19.48)                  | 1.89         | 0.162   |
| **RNFL Thickness**   |                        |                                 |                                 |              |         |
| Superior Disc        | 122.38 (17.30)         | 120.73 (15.98)                  | 120.38 (16.57)                  | 1.12         | 0.334   |
| Temporal Disc        | 70.89 (18.03)          | 67.92 (17.76)                   | 68.81 (17.96)                   | 3.42         | 0.041*  |
| Inferior Disc        | 128.96 (20.37)         | 126.81 (20.12)                  | 125.58 (20.28)                  | 3.02         | 0.058   |
| Nasal Disc           | 68.35 (11.63)          | 67.58 (12.42)                   | 67.73 (11.41)                   | 0.20         | 0.816   |

SD: Standard Deviation; *: Statistical significance (P<0.05)

Note: Power of the study is 0.9

### Table 4: Post-hoc Bonferroni correction to establish changes of the significant retina thinning from Table 4

| Right Eye | Pre-treatment and 3 months | Pre-treatment and 6 months |
|-----------|---------------------------|---------------------------|
|           | MD (95% CI)               | p-value                   |
| Superior Parafoveal | 2.35 (-0.16, 4.85)       | 0.071                     |
| Temporal Parafoveal   | 2.69 (-0.71, 6.10)       | 0.159                     |
| Inferior Parafoveal   | 2.00 (0.11, 3.89)        | 0.035*                    |
| Temporal Disc          | 2.96 (-0.37, 6.29)       | 0.094                     |
|                       | 8.19 (-2.59, 18.97)      | 0.187                     |
|                       | 2.89 (-0.18, 5.95)       | 0.070                     |
|                       | 4.89 (0.34, 9.43)        | 0.032*                    |
|                       | 2.08 (-0.79, 4.95)       | 0.226                     |

MD= mean difference; *: Statistical significance (P<0.05)

### Table 5: Linear Regression analysis to predict future thinning in the perifoveal areas and mean optic disc RNFL on parafoveal thinning from Table 4.

| Areas               | β (95% CI) | t statistic (df) | p-value | r²      |
|---------------------|------------|------------------|---------|---------|
| Total area          | 0.30 (0.23, 0.37) | 8.65 (24) | <0.001* | 0.757   |
| Foveal              | 0.27 (0.03, 0.50) | 2.35 (24) | 0.027*  | 0.188   |
| Perifoveal          | 0.95 (0.74, 1.16) | 9.33 (24) | <0.001* | 0.784   |
| Mean Optic Disc     | 0.73 (0.26,1.19) | 3.22 (24) | <0.004* | 0.302   |
| RNFL**              |            |                  |         |         |

*: Statistical significance (P<0.05)

**: Mean of superior, temporal, inferior, and nasal quadrants of optic disc RNFL thickness

Our study also showed RNFL thinning (at temporal quadrant) (Table 3) in patients taking hydroxychloroquine but compared to the macula thinning we could not establish a significant change at 3 months or 6 months (Table 4). There are limited studies in this area. GY Liu et al. showed that there is significant retinal nerve layer thinning besides macula thinning in SLE patients with chronic hydroxychloroquine usage. Another study found the patients using hydroxychloroquine for a mean of 13.4 years had thinner mean retinal nerve fiber layers values than healthy patients. Interestingly, an older study found significant thinning of RNFL nasal quadrant using quantitative analysis at 5 years of usage and postulated that it because of significant retinal ganglion cell degeneration. Measurement of the macular ganglion cell-inner plexiform layer (GC-IPL) over time may establish a new link this toxicity.

The main limitation of our study is a short time of observation as further follow-ups could show transformation into structural defects. We also cannot measure the blood hydroxychloroquine level to establish compliance as proper testing is unreliable or still in

studies to identify the nature of the toxicity and performing appropriate screening tests.
development.

The fundamental challenge in managing retinal hydroxychloroquine toxicity is the possibility of toxicity before 5 years of usage. A large population study conducted in the United Kingdom in 2018 showed excess dosing of hydroxychloroquine than the recommended ophthalmology level as it is quite commonly prescribed as 200mg or 400mg daily dose. Another study also revealed that half of the patients had weight documented before prescription but not used to determine the doses. Further, a safe dose of 5mg/kg real bodyweight places short, obese patients at unnecessarily increased risk for retinopathy. It is also not uncommon that patients may develop renal disease or experience weight loss (and a higher dose) after 1 year and these patients will probably not realize they are at high risk and will go without follow-up for 4 more years. Meanwhile, only 86% were aware that they require eye checks after five years of hydroxychloroquine use, and even worse, 20% were not compliant. Also, these patients’ eye reports are likely hard to acquire after 5 years.

Addressing this challenge, SD-OCT is crucial for the detection of early hydroxychloroquine retinal toxicity. And once the toxicity was detected, and the drug withheld before RPE damage, the progression is mild and limited (Reversible toxicity). If the drug is continued, the area of functional disturbance expands with RPE involvement and encroach fovea and stopping the drug in this stage will not prevent further deterioration of vision (Irreversible toxicity). Second SD-OCT imaging performed before 5-years duration, after baseline assessment may detect potential earliest retina thinning and, once there is a thinning, other modalities such as HVF 10-2, FAF, or mfERG could be used. SD-OCT also easily available and could be a cost-effective way of screening. The future applications of OCT include OCT angiography to detect the earliest microvascular changes and the wide-angle mode swept source OCT (SS-OCT) for its accuracy and a wider area. In summary, SD-OCT could evaluate potential hydroxychloroquine retinal toxicity better, and we should perform it early and repeatedly.

5. Source of Funding

This work is not supported by any research grant.

6. Conflict of Interest

The authors declare that they have no competing interests.

7. Acknowledgments

We are indebted to the Rheumatological, Medical, and Dermatological departments of Hospital Raja Permaisuri Bainun contributing for the patients’ pool as well as to Dr. Siti Azrin Abdul Hamid and Liu Kien Ting from the Department of Biostatistics and Research Methodology who assisted us during proposal preparation and statistical analysis respectively.

References

1. Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014;5(4):77–85.
2. Sharma TS, Wasko MCM, Tang X, Vedumurthy D, Yan X, Cote J, et al. Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc. 2016;5(1):e002867.
3. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911.
4. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–9.
5. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60.
6. Xu C, Zha L, Chan T, Lu X, Shen W, Madigan MC. Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2. J Pharm Sci. 2016;105(2):884–90.
7. Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci. 1978;17(12):1158–75.
8. Karpik AG, Schwartz MM, Dickey LE, Streeter BW, Roberts JL. Ocular immune reactants in patients dying with systemic lupus erythematosus. Clin Immunol Immunopathol. 1985;35(3):295–312.
9. Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? J Ophthalmol. 2001;131(6):761–6.
10. Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016;68(1):184–90.
11. Rodriguez-Padilla JA, Hedges TR, Monson B, Srinivasan V, Wojtkowski M, Reichel F, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007;125(6):775–80.
12. Marmor MF. Comparison of Screening Procedures in Hydroxychloroquine Toxicity. Arch Ophthalmol. 2012;130(4):461–9.
13. Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clin Ophthalmol (Auckland, NZ). 2010;4:1151–8.
14. Çay HF, Erol MK, Çoban DT, Buhut M, Sezer I, Çakır T, et al. Retinotoxicity of Hydroxychloroquine: Is It Possible to Demonstrate by Spectral Domain Optical Coherence Tomography Before Development? A Cross Sectional Investigation. Arch Rheumatol. 2014;29(3):178–85.
15. Kan E, Yakar K, Demirag MD, Gok M. Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine. Int Ophthalmol. 2018;38(4):1635–40.
16. Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, et al. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. Arthritis Res Ther. 201805;20(1):133.
17. Braslow RA, Shiloach M, Macsai MS. Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System. Ophthalmol. 2017;124(5):604–8.
18. Saravanan A, Ahmed T. SAT0222 Clinical risk stratification for hydroxychloroquine prescribing in a large urban district general hospital. *Ann Rheum Dis*. 2018;77(Suppl 2):972.

19. Liu GY, Utset TO, Bernard JT. Retinal nerve fiber layer and macular thinning in systemic lupus erythematosus: an optical coherence tomography study comparing SLE and neuropsychiatric SLE. *Lupus*. 2015;24(11):1169–76.

20. Browning DJ, Lee C. Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines. *Clin Ophthalmol*. 2018;12:811–8.

21. Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). *Ophthalmology*. 2016;123:1386–94.

22. Pasadhika S, Fishman GA. Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. *Eye (Lond)*. 2010;24(2):340–6.

23. Martín-Iglesias D, Artaraz J, Fonolllosa A, Ugarte A, Arteagabeitia A, Ruiz-Irastorza G. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. *Lupus*. 2019;28(4):555–9.

24. Gil P, Nunes A, Farinha C, Teixeira D, Pires I, Silva R. Structural and Functional Characterization of the Retinal Effects of Hydroxychloroquine Treatment in Healthy Eyes. *Ophthalmologica*. 2019;241(4):226–33.

25. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. *Ophthalmology*. 2015;122(1):110–6.

26. Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK. Pericentral hydroxychloroquine retinopathy in Korean patients. *Ophthalmology*. 2015;122(6):1252–6.

27. Eo D, Lee MG, Ham DI, Kang SW, Lee J, Cha HS. Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases. *J Korean Med Sci*. 2017;32(3):522–7.

28. Sisternes LD, Hu J, Rubin DL, Marmor MF. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. *Invest Ophthalmol Vis Sci*. 2015;56(5):3415–26.

29. Sunmboye K, Shaffu S, Mccartney M. PS6:113 Long-term hydroxychloroquine use: are lupus patients undermonitored?: a university teaching hospital experience. *Lupus Sci Med*. 2018;5(Suppl 1):92.

30. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. *JAMA Ophthalmol*. 2014;132(9):1105–12.

31. Bulut M, Akıdan M, Gözkaya O, Erol MK, Cengiz A, Çay HF. Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations. *Graefes Arch Clin Exp Ophthalmol*. 2018;256(11):2075–81.

32. Ahn SJ, Joung J, Lee BR. En Face Optical Coherence Tomography Imaging of the Photoreceptor Layers in Hydroxychloroquine Retinopathy. *Am J Ophthalmol*. 2019;199:71–81.

Author biography

Logandran Vijaya Kumar, Ophthalmologist [https://orcid.org/0000-0002-0013-1508](https://orcid.org/0000-0002-0013-1508)

Kursiah Mohd Razali, Ophthalmologist

Wan Hazabbah Wan Hitam, Professor

Cite this article: Kumar LV, Razali KM, Hitam WHW. Hydroxychloroquine retinal toxicity- Can we do better with SD-OCT?. *Indian J Clin Exp Ophthalmol*. 2021;7(3):457-465.